MED-EXEMESTANE 25 MG
EXEMESTANE : 25 MG · DIN 02407841 · GENERIC MEDICAL PARTNERS INC
Health Canada status: MARKETED
What is MED-EXEMESTANE?
MED-EXEMESTANE 25 MG contains EXEMESTANE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02407841, held by GENERIC MEDICAL PARTNERS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 02-Dec-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MED-EXEMESTANE used for?
MED-EXEMESTANE (exemestane tablets) is indicated for the sequential adjuvant treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy. It is also indicated for hormonal treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status whose disease has progressed following antiestrogen therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02407841 |
|---|---|
| Brand name | MED-EXEMESTANE |
| Generic / active ingredient | EXEMESTANE : 25 MG |
| Manufacturer | GENERIC MEDICAL PARTNERS INC |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L02BG06 EXEMESTANE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Dec-2013 |
| Original market date | 2013-12-02 00:00:00 |
How is it administered?
25 mg once daily after a meal. In early breast cancer, continue for 5 years of adjuvant endocrine therapy. In advanced breast cancer, continue until tumor progression.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
PVC/PVDC/Aluminum blisters of 2 strips of 15 tablets (30 tablets total).
Contraindications
Hypersensitivity to the drug or any ingredient. Contraindicated in women who are or may become pregnant.
Warnings and precautions
Not for pre-menopausal women. Risk of ischemic cardiovascular diseases, hypercholesterolemia, gastric ulcer, and reduced bone mineral density (BMD). Monitor for tendonitis/tendon rupture.
What can be used instead?
Other Canadian products sharing ATC code L02BG06 EXEMESTANE. 3 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT EXEMESTANE | 25 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02390183 |
| AROMASIN | 25 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02242705 |
| APO-EXEMESTANE | 25 MG | TABLET | APOTEX INC | DORMANT | DIN 02419726 |
| GD-EXEMESTANE | 25 MG | TABLET | GENMED A DIVISION OF PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02359693 |
| MYLAN-EXEMESTANE | 25 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED PRE MARKET | DIN 02405075 |
| TEVA-EXEMESTANE | 25 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02408473 |
Who else supplies EXEMESTANE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. EXEMESTANE appears in 168 registered pack listings across 14 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.